Natural Killer (NK) cells are known to reject several experimental murine tumors, but their antineoplastic activity in humans is not generally agreed upon, as exemplified by an interesting correspondence recently appeared in Cancer Research. In the present commentary, we join the discussion and bring to the attention of the readers of the Journal of Translational Medicine a set of recent, related reports. These studies demonstrate that effectors of the adaptive and innate immunity need to actively cooperate in order to reject tumors and, conversely, tumors protect themselves by dampening both T and NK cell responses. The recently reported ability of indoleamine 2,3-dioxygenase (IDO) and prostaglandin E2 (PGE2) expressed by melanoma cells to down-regulate activating NK receptors is yet another piece of evidence supporting combined and highly effective T/NK cell disabling. Major Histocompatibility Complex class I (MHC-I) molecules, including Human Leukocyte Antigen E (HLA-E), represent another class of shared activating/inhibitory ligands. Ongoing clinical trials with small molecules interfering with IDO and PGE2 may be exploiting an immune bonus to control cancer. Conversely, failure to simultaneously engage effectors of both the innate and the adaptive immunity may contribute to explain the limited clinical efficacy of T cell-only vaccination trials. Shared (T/NK cells) natural immunosuppressants and activating/inhibitory ligands expressed by tumor cells may provide mechanistic insight into impaired gathering and function of immune effectors at the tumor site.

Fruci, D., Lo Monaco, E., Cifaldi, L., Locatelli, F., Tremante, E., Benevolo, M., Giacomini, P., T and NK cells: two sides of tumor immunoevasion, <<JOURNAL OF TRANSLATIONAL MEDICINE>>, 2013; 11 (1): N/A-N/A. [doi:10.1186/1479-5876-11-30] [https://hdl.handle.net/10807/244296]

T and NK cells: two sides of tumor immunoevasion

Locatelli, Franco;
2013

Abstract

Natural Killer (NK) cells are known to reject several experimental murine tumors, but their antineoplastic activity in humans is not generally agreed upon, as exemplified by an interesting correspondence recently appeared in Cancer Research. In the present commentary, we join the discussion and bring to the attention of the readers of the Journal of Translational Medicine a set of recent, related reports. These studies demonstrate that effectors of the adaptive and innate immunity need to actively cooperate in order to reject tumors and, conversely, tumors protect themselves by dampening both T and NK cell responses. The recently reported ability of indoleamine 2,3-dioxygenase (IDO) and prostaglandin E2 (PGE2) expressed by melanoma cells to down-regulate activating NK receptors is yet another piece of evidence supporting combined and highly effective T/NK cell disabling. Major Histocompatibility Complex class I (MHC-I) molecules, including Human Leukocyte Antigen E (HLA-E), represent another class of shared activating/inhibitory ligands. Ongoing clinical trials with small molecules interfering with IDO and PGE2 may be exploiting an immune bonus to control cancer. Conversely, failure to simultaneously engage effectors of both the innate and the adaptive immunity may contribute to explain the limited clinical efficacy of T cell-only vaccination trials. Shared (T/NK cells) natural immunosuppressants and activating/inhibitory ligands expressed by tumor cells may provide mechanistic insight into impaired gathering and function of immune effectors at the tumor site.
2013
Inglese
Fruci, D., Lo Monaco, E., Cifaldi, L., Locatelli, F., Tremante, E., Benevolo, M., Giacomini, P., T and NK cells: two sides of tumor immunoevasion, <<JOURNAL OF TRANSLATIONAL MEDICINE>>, 2013; 11 (1): N/A-N/A. [doi:10.1186/1479-5876-11-30] [https://hdl.handle.net/10807/244296]
File in questo prodotto:
File Dimensione Formato  
T and NK cells.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Note: http://creativecommons.org/licenses/by/2.0
Licenza: Creative commons
Dimensione 1.07 MB
Formato Adobe PDF
1.07 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/244296
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 30
social impact